ABIOMED, INC.  AND SUBSIDIARIES Notes to Consolidated Financial Statements—(Continued) Note 15.
Commitments and Contingencies (Continued) The Company applies the disclosure provisions of FIN No.45, Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Guarantees of Indebtedness of Others, and Interpretation of FASB Statements No.5, 57 and 107 and Rescission of FASB Interpretation No.34 (FIN No.45) to its agreements that contain guarantee or indemnification clauses.
These disclosure provisions expand those required by SFAS No.5, Accounting for Contingencies, by requiring that guarantors disclose certain types of guarantees, even if the likelihood of requiring the guarantor’s performance is remote.
In addition to product warranties, the following is a description of arrangements in which the Company is a guarantor.
Indemnifications—In many sales transactions, the Company indemnifies customers against possible claims of patent infringement caused by the Company’s products.
The indemnifications contained within sales contracts usually do not include limits on the claims.
The Company has never incurred any material costs to defend lawsuits or settle patent infringement claims related to sales transactions.
Under the provisions of FIN No.45, intellectual property indemnifications require disclosure only.
The Company enters into agreements with other companies in the ordinary course of business, typically with underwriters, contractors, clinical sites and customers that include indemnification provisions.
Under these provisions the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities.
These indemnification provisions generally survive termination of the underlying agreement.
The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited.
Abiomed has never incurred any material costs to defend lawsuits or settle claims related to these indemnification agreements.
As a result, the estimated fair value of these agreements is minimal.
Accordingly, the Company has no liabilities recorded for these agreements as of March 31, 2008.
Clinical study agreements—In the Company’s clinical study agreements, Abiomed has agreed to indemnify the participating institutions against losses incurred by them for claims related to any personal injury of subjects taking part in the study to the extent they relate to uses of the Company’s devices in accordance with the clinical study agreement, the protocol for the device and Abiomed’s instructions.
The indemnification provisions contained within the Company’s clinical study agreements do not generally include limits on the claims.
The Company has never incurred any material costs related to the indemnification provisions contained in its clinical study agreements.
Facilities Leases—As of March 31, 2008, the Company had entered into leases for its facilities, including its primary operating facility in Danvers, Massachusetts with terms through fiscal 2010.
The Danvers lease may be extended, at the Company’s option, for two successive additional periods of five years each with monthly rent charges to be determined based on then current fair rental values.
The Company’s lease for its Aachen location expires in December 2012.
Total rent expense under these leases, included in the accompanying consolidated statements of operations approximated $2.2 million, $1.6 million, and $1.3 million for the fiscal years ended March 31, 2008, 2007 and 2006, respectively.
Future minimum lease payments under all significant non-cancelable operating leases as of March 31, 2008 are approximately as follows:
## Table 0 ##
Litigation—From time-to-time, the Company is involved in legal and administrative proceedings and claims of various types.
While any litigation contains an element of uncertainty, management presently believes that the outcome of each such other proceedings or claims which are pending or known to be threatened, or all of them combined, is not expected to have a material adverse effect on the Company’s financial position, cash flow and results.
Investments of the Plan are accounted for at cost on the trade date and are reported at fair value.
All of the Plan’s investments at December 31, 2011 are classified as Level 1 within the fair value hierarchy.
In general, investments of the Plan are exposed to various risks, such as interest rate risk, credit risk, and overall market volatility.
Due to the level of risk associated with certain investments, it is reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect the amounts reported in the Plan assets.
The investment objective of the Plan is to maximize the return on Plan assets over a long time horizon, while meeting the Plan obligations.
At December 31, 2011, Plan assets were invested 61% in equity investments and 32% in bonds, with an average duration of 3.3 years on fixed income investments.
The estimated life of benefit obligations was 13 years.
Management believes that this mix is appropriate for the current economic environment.
Although it may fluctuate with market conditions, Management has targeted a long-term allocation of Plan assets of 70% in equity investments and 30% in bond investments.
The following table shows the number of shares and dividends received on shares of Huntington stock held by the Plan:
## Table 1 ##
(1) The Plan has acquired and held Huntington common stock in compliance at all times with Section 407 of the Employee Retirement Income Security Act of 1978.
At December 31, 2011, the following table shows when benefit payments, which include expected future service, as appropriate, were expected to be paid:
## Table 2 ##
Although not required, Huntington may choose to make a cash contribution to the Plan up to the maximum deductible limit in the 2012 plan year.
Anticipated contributions for 2012 to the post-retirement benefit plan are $3.5 million.
The assumed healthcare cost trend rate has an effect on the amounts reported.
A one percentage point increase would decrease service and interest costs and the post-retirement benefit obligation by less than $1.0 million and $0.2 million, respectively.
A one percentage point decrease would increase service and interest costs and the post-retirement benefit obligation by less than $1.0 million and $0.2 million, respectively.
The 2012 and 2011 healthcare cost trend rate was projected to be 8.0% for pre-65 aged participants and 8.5% for post-65 aged participants.
These rates are assumed to decrease gradually until they reach 4.5% for both pre-65 aged participants and post-65 aged participants in the year 2028 and remain at that level thereafter.
Huntington updated the immediate healthcare cost trend rate assumption based on current market data and Huntington’s claims experience.
This trend rate is expected to decline over time to a trend level consistent with medical inflation and long-term economic assumptions.
The following table reflects activity in the ALLL and ACL for each of the last five years.
Table 18 — Summary of Allowance for Credit Losses and Related Statistics
## Table 3 ##

<table><tr><td>Fiscal Year Ending March 31,</td><td>Operating Leases  (in $000’s)</td></tr><tr><td>2009</td><td>2,544</td></tr><tr><td>2010</td><td>2,220</td></tr><tr><td>2011</td><td>1,287</td></tr><tr><td>2012</td><td>973</td></tr><tr><td>2013</td><td>730</td></tr><tr><td>Thereafter</td><td>—</td></tr><tr><td>Total future minimum lease payments</td><td>$7,754</td></tr></table>
<table><tr><td></td><td colspan="2"> December 31,</td></tr><tr><td></td><td> 2011</td><td> 2010</td></tr><tr><td> (dollar amounts in millions, except share amounts)</td><td></td><td></td></tr><tr><td>Shares in Huntington common stock-1</td><td>7,309,986</td><td>3,919,986</td></tr><tr><td>Dividends received on shares of Huntington stock</td><td>$0.4</td><td>$0.2</td></tr></table>
<table><tr><td></td><td> Pension Benefits</td><td> Post- Retirement Benefits</td></tr><tr><td> (dollar amounts in thousands)</td><td></td><td></td></tr><tr><td>2012</td><td>$34,124</td><td>$4,297</td></tr><tr><td>2013</td><td>36,006</td><td>4,110</td></tr><tr><td>2014</td><td>36,874</td><td>3,923</td></tr><tr><td>2015</td><td>38,573</td><td>3,759</td></tr><tr><td>2016</td><td>40,533</td><td>3,588</td></tr><tr><td>2017 through 2021</td><td>225,480</td><td>15,694</td></tr></table>
<table><tr><td></td><td colspan="5">Year Ended December 31,</td></tr><tr><td></td><td>2011</td><td>2010</td><td>2009</td><td>2008</td><td>2007</td></tr><tr><td> (dollar amounts in thousands)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Allowance for loan and lease losses, beginning of year</td><td>$1,249,008</td><td>$1,482,479</td><td>$900,227</td><td>$578,442</td><td>$272,068</td></tr><tr><td> Acquired allowance for loan and lease losses</td><td>—</td><td>—</td><td>—</td><td>—</td><td>188,128</td></tr><tr><td> Loan and lease charge-offs</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Commercial:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Commercial and industrial</td><td>-134,385</td><td>-316,771</td><td>-525,262</td><td>-538,434</td><td>-359,457</td></tr><tr><td>Commercial real estate:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Construction</td><td>-42,012</td><td>-116,428</td><td>-196,148</td><td>-6,631</td><td>-11,902</td></tr><tr><td>Commercial</td><td>-140,747</td><td>-187,567</td><td>-500,534</td><td>-65,565</td><td>-29,152</td></tr><tr><td>Commercial real estate</td><td>-182,759</td><td>-303,995</td><td>-696,682</td><td>-72,196</td><td>-41,054</td></tr><tr><td>Total commercial</td><td>-317,144</td><td>-620,766</td><td>-1,221,944</td><td>-610,630</td><td>-400,511</td></tr><tr><td>Consumer:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Automobile</td><td>-33,593</td><td>-46,308</td><td>-76,141</td><td>-72,108</td><td>-41,241</td></tr><tr><td>Home equity</td><td>-109,427</td><td>-140,831</td><td>-110,400</td><td>-70,457</td><td>-37,221</td></tr><tr><td>Residential mortgage</td><td>-65,069</td><td>-163,427</td><td>-111,899</td><td>-23,012</td><td>-12,196</td></tr><tr><td>Other consumer</td><td>-32,520</td><td>-32,575</td><td>-40,993</td><td>-30,123</td><td>-26,773</td></tr><tr><td>Total consumer</td><td>-240,609</td><td>-383,141</td><td>-339,433</td><td>-195,700</td><td>-117,431</td></tr><tr><td> Total charge-offs</td><td>-557,753</td><td>-1,003,907</td><td>-1,561,378</td><td>-806,330</td><td>-517,942</td></tr><tr><td> Recoveries of loan and lease charge-offs</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Commercial:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Commercial and industrial</td><td>44,686</td><td>61,839</td><td>37,656</td><td>12,269</td><td>13,617</td></tr><tr><td>Commercial real estate:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Construction</td><td>10,488</td><td>7,420</td><td>3,442</td><td>5</td><td>48</td></tr><tr><td>Commercial</td><td>24,170</td><td>21,013</td><td>10,509</td><td>3,451</td><td>1,902</td></tr><tr><td>Total commercial real estate</td><td>34,658</td><td>28,433</td><td>13,951</td><td>3,456</td><td>1,950</td></tr><tr><td>Total commercial</td><td>79,344</td><td>90,272</td><td>51,607</td><td>15,725</td><td>15,567</td></tr><tr><td>Consumer:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Automobile</td><td>18,526</td><td>19,736</td><td>19,809</td><td>17,543</td><td>13,549</td></tr><tr><td>Home equity</td><td>7,630</td><td>1,458</td><td>4,224</td><td>2,901</td><td>2,795</td></tr><tr><td>Residential mortgage</td><td>8,388</td><td>10,532</td><td>1,697</td><td>1,765</td><td>825</td></tr><tr><td>Other consumer</td><td>6,776</td><td>7,435</td><td>7,454</td><td>10,329</td><td>7,575</td></tr><tr><td>Total consumer</td><td>41,320</td><td>39,161</td><td>33,184</td><td>32,538</td><td>24,744</td></tr><tr><td> Total recoveries</td><td>120,664</td><td>129,433</td><td>84,791</td><td>48,263</td><td>40,311</td></tr><tr><td> Net loan and lease charge-offs</td><td>-437,089</td><td>-874,474</td><td>-1,476,587</td><td>-758,067</td><td>-477,631</td></tr><tr><td>Provision for loan and lease losses</td><td>167,730</td><td>641,299</td><td>2,069,931</td><td>1,067,789</td><td>628,802</td></tr><tr><td>Economic reserve transfer</td><td>—</td><td>—</td><td>—</td><td>12,063</td><td>—</td></tr><tr><td>Allowance for assets sold and securitized or transferred to loans held for sale</td><td>-14,821</td><td>-296</td><td>-11,092</td><td>—</td><td>-32,925</td></tr><tr><td> Allowance for loan and lease losses, end of year</td><td>964,828</td><td>1,249,008</td><td>1,482,479</td><td>900,227</td><td>578,442</td></tr><tr><td>Allowance for unfunded loan commitments, beginning of year</td><td>42,127</td><td>48,879</td><td>44,139</td><td>66,528</td><td>40,161</td></tr><tr><td>Acquired allowance for unfunded loan commitments</td><td>—</td><td>—</td><td>—</td><td>—</td><td>11,541</td></tr><tr><td>(Reduction in) Provision for unfunded loan commitments and letters of credit losses</td><td>6,329</td><td>-6,752</td><td>4,740</td><td>-10,326</td><td>14,826</td></tr><tr><td>Economic reserve transfer</td><td>—</td><td>—</td><td>—</td><td>-12,063</td><td>—</td></tr><tr><td> Allowance for unfunded loan commitments, end of year</td><td>48,456</td><td>42,127</td><td>48,879</td><td>44,139</td><td>66,528</td></tr><tr><td> Allowance for credit losses, end of year</td><td>$1,013,284</td><td>$1,291,135</td><td>$1,531,358</td><td>$944,366</td><td>$644,970</td></tr><tr><td>ALLL as a % of total period end loans and leases</td><td>2.48%</td><td>3.28%</td><td>4.03%</td><td>2.19%</td><td>1.44%</td></tr><tr><td>AULC as a % of total period end loans and leases</td><td>0.12</td><td>0.11</td><td>0.13</td><td>0.11</td><td>0.17</td></tr><tr><td> ACL as a % of total period end loans and leases</td><td>2.60%</td><td>3.39%</td><td>4.16%</td><td>2.30%</td><td>1.61%</td></tr></table>

Question: What is the increasing rate of Total recoveries between 2009 and 2010?
Answer: 0.52649